AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca says vaccine adjustments for new variants need six months

The company aims to cut the time to mass-produce its shot to between six and nine months, as it revealed that annual profits more than doubled.

AstraZeneca Focuses on Adapting Vaccine for New Covid-19 Strains as Annual Profits Double

AstraZeneca plc (NASDAQ: AZN) expects profit growth to pick up this year after announcing better than expected quarterly drug sales, with demand for its cancer and other therapies cushioning the disruption caused by the pandemic. Fourth-quarter net income rose to $1.01 billion from $313 million a year ago.

AstraZeneca Sees Profit Growth In 2021 Despite COVID-19 Vaccine Controversy

In a report on Thursday, AstraZeneca plc (LON: AZN) said its pre-tax profit came in better than last year in the fiscal fourth quarter. The company expressed confidence that its financial performance will remain upbeat in 2021 on the back of core earnings and revenue that also jumped in Q4.

AstraZeneca's revenue jumps 11% in the fiscal fourth quarter

Anglo-Swedish pharmaceutical firm's profits rise to $7.4bn as main business ‘remains strong'

AstraZeneca says vaccine against new Covid variants may take six months

AstraZeneca PLC (LON:AZN) said it expects to deliver full-year revenue growth of 11-12% even excluding sales from the COVID-19 vaccine. The FTSE 100 pharma giant said it will report them separately from the next quarter, while it will continue investing in research and development and in the support of medicines and patient access in key markets over the year.

AstraZeneca expects 11-12% full-year revenue growth without counting COVID-19 vaccine

AstraZeneca has featured prominently in 2020 because of its coronavirus jab, although it has said will not profit from the vaccine during the pandemic.

AstraZeneca sales rise 10% in a year dominated by the coronavirus

AstraZeneca on Thursday forecast 2021 revenue growth after the COVID-19 vaccine developer beat analysts' estimates for fourth-quarter product sales, as a wide range of therapies helped cushion the hit from the pandemic.

AstraZeneca forecasts 2021 growth after fourth-quarter sales beat

Manufacturing site to be built in partnership with IDT Biologika to help defuse row with EU over supply

AstraZeneca to build new Covid-19 vaccine facility in Germany

The world will be eyeing AstraZeneca PLC (LON:AZN) as it releases full-year results on Thursday and whilst the headlines will feature the obvious keywords, there is more going on than just a vaccine. Although the focus has been on the COVID-19 vaccine developed by Oxford University and the pharma giant's recent row with the EU, the market will be looking at the FTSE 100 group's drug pipeline, especially after the recent approvals for cancer and respiratory drugs.

AstraZeneca and Royal Mail in the spotlight on Thursday

AstraZeneca Plc (NASDAQ: AZN) enlists Germany's IDT Biologika as a contract manufacturer of its COVID-19 vaccine. Both the companies are exploring options to accelerate the output of the finished COVID-19 vaccine in the second quarter of 2021 to help support Europe's immediate vaccination needs during the pandemic following the European Medicines Agency approval on January 29.

AstraZeneca Recruits IDT Biologika As Manufacturing Partner For COVID-19 Vaccine

AstraZeneca (NYSE:AZN) announces its next round of earnings this Thursday, February 11. Here is Benzinga's everything-that-matters guide for this Thursday's Q4 earnings announcement.

Earnings Outlook For AstraZeneca

Johnson & Johnson

The significant policy change is based on a small study that has not undergone peer review and did not evaluate the vaccine's protection against severe disease, a key metric of success.

South Africa Abandons Oxford-AstraZeneca Covid-19 Vaccine In Favor Of Unapproved Johnson & Johnson Shot

NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the “Class Period”).

Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against AstraZeneca PLC – AZN

Kraft Heinz

PepsiCo

Duke Energy

Earnings season is starting to wind down, but some major companies are still reporting their most recent quarterly results this week.

Thursday Morning Earnings Watch List: AstraZeneca, Duke, Kraft Heinz, and Pepsi

From doubts about safety in older people to questions about variants, scientists have faced a battle to convince the public and regulators

A series of knocks: Oxford/AstraZeneca's bumpy road to Covid vaccine confidence

Amazon

3 No-Brainer Growth Stocks Begging to Be Bought

Officials in the U.K. and Australia tried to reassure their citizens about the efficacy of the AstraZeneca–Oxford University COVID-19 vaccine.

AstraZeneca COVID-19 vaccine concerns shrugged off by U.K. and Australia

AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales. However, coronavirus-led disruption is likely to have hurt sales.

What's in Store for AstraZeneca (AZN) This Earnings Season?

The global case tally of confirmed cases of the coronavirus-borne illness COVID-19 climbed above 107 million on Monday, with the U.S. accounting for more than 27 million of that total, even as cases continue to decline and the post-holiday surge abates.

Coronavirus Update: U.S. COVID case tally tops 27 million, while South Africa abandons AstraZeneca vaccine

The study did not evaluate the shot's effect on preventing severe illness, a key measure of success.

South Africa Halts AstraZeneca Covid-19 Vaccine After Study Shows ‘Minimal Protection' Against Local Variant

AstraZeneca Plc (NASDAQ: AZN) is working on a new version of its COVID-19 vaccine for immunity against the South African coronavirus variant after a small early data suggested that AZN's jab has limited protection against mild disease caused by the variant, Bloomberg reports. Sarah Gilbert, leading the Oxford University-AstraZeneca vaccine program, said work was already underway, and the new shot is “very likely” to be available by autumn.

South Africa Halts AstraZeneca's COVID-19 Vaccine Rollout On Efficacy Against Variant

Concerns about the effectiveness of AstraZeneca PLC's (LON:AZN) against new variants of coronavirus grew today as South Africa stopped administering the drug. New research indicated the vaccine gave little protection against mild infections in young people of the so-called South African variant, though it did better against more severe infections.

South Africa stops use of AstraZeneca vaccine due to new variant worries

Drugmaker AstraZeneca is racing to adapt its Covid-19 vaccine in the face of new variants of the virus.

AstraZeneca races to adapt Covid vaccine as South Africa suspends rollout

The Anglo-Swedish firm already had a strong lineup of cancer drugs when vaccine success gave it a further boost

News for AstraZeneca Stock (AZN)